Aspirin for venous ulcers: randomised trial (AVURT): study protocol for a randomised controlled trial

Tilbrook, H., Forsythe, R.O., Rolfe, D., Clark, L., Bland, M., Buckley, H., Chetter, I., Cook, L., Dumville, J., Gabe, R., Harding, K., Layton, A., Lindsay, E., McDaid, C., Moffatt, C. ORCID: 0000-0002-2436-0129, Phillips, C., Stansby, G., Vowden, P., Williams, L., Torgerson, D. and Hinchliffe, R.J., 2015. Aspirin for venous ulcers: randomised trial (AVURT): study protocol for a randomised controlled trial. Trials, 16 (1): 513. ISSN 1745-6215

[img]
Preview
Text
12249_Moffatt.pdf - Published version

Download (430kB) | Preview

Abstract

Background: Venous leg ulcers (VLUs) are the commonest cause of leg ulceration, affecting 1 in 100 adults. There is a significant health burden associated with VLUs – it is estimated that the cost of treatment for 1 ulcer is up to £1300 per year in the NHS. The mainstay of treatment is with graduated compression bandaging; however, treatment is often prolonged and up to one quarter of venous leg ulcers do not heal despite standard care. Two previous trials have suggested that low-dose aspirin, as an adjunct to standard care, may hasten healing, but these trials were small and of poor quality. Aspirin is an inexpensive, widely used medication but its safety and efficacy in the treatment of VLUs remains to be established.

Methods/Design: AVURT is a phase II randomised double blind, parallel-group, placebo-controlled efficacy trial. The primary objective is to examine whether aspirin, in addition to standard care, is effective in patients with chronic VLUs (i.e. over 6 weeks in duration or a history of VLU). Secondary objectives include feasibility and safety of aspirin in this population. A target of 100 participants, identified from community leg ulcer clinics and hospital clinics, will be randomised to receive either 300 mg of aspirin once daily or placebo. All participants will receive standard care with compression therapy. The primary outcome will be time to healing of the reference ulcer. Follow-up will occur for a maximum of 27 weeks. The primary analysis will use a Cox proportional hazards model to compare time to healing using the principles of intention-to-treat. Secondary outcomes will include ulcer size, pain evaluation, compliance and adverse events.

Discussion: The AVURT trial will investigate the efficacy and safety of aspirin as a treatment for VLU and will inform on the feasibility of proceeding to a larger phase III study. This study will address the paucity of information currently available regarding aspirin therapy to treat VLU.

Trial registration: The study is registered on a public database with clinicaltrials.gov (NCT02333123; registered on 5 November 2014).

Item Type: Journal article
Publication Title: Trials
Creators: Tilbrook, H., Forsythe, R.O., Rolfe, D., Clark, L., Bland, M., Buckley, H., Chetter, I., Cook, L., Dumville, J., Gabe, R., Harding, K., Layton, A., Lindsay, E., McDaid, C., Moffatt, C., Phillips, C., Stansby, G., Vowden, P., Williams, L., Torgerson, D. and Hinchliffe, R.J.
Publisher: BioMed Central
Date: 2015
Volume: 16
Number: 1
ISSN: 1745-6215
Identifiers:
NumberType
10.1186/s13063-015-1039-9DOI
Rights: © 2018 BioMed Central Ltd. Part of Springer Nature.
Divisions: Schools > School of Social Sciences
Depositing User: Linda Sullivan
Date Added: 19 Oct 2018 08:43
Last Modified: 19 Oct 2018 08:43
URI: http://irep.ntu.ac.uk/id/eprint/34700

Actions (login required)

Edit View Edit View

Views

Views per month over past year

Downloads

Downloads per month over past year